- PR Newswire•12 days ago
BASEL, Switzerland, February 8, 2017 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd announced today the expansion of its commercial operations in Europe with the introduction of its portfolio of generics ...
- American City Business Journals•13 days ago
Rare-disease drug developer BioMarin Pharmaceutical Inc. sued an Indian drug maker that plans to make and sell a version of one of BioMarin's top-selling drugs. The San Rafael company (BMRN), led by CEO Jean-Jacques Bienaimé, said in a filing Monday in U.S. District Court in New Jersey that a version of the drug Kuvan by Dr. Reddy's Laboratories Ltd. infringes on six BioMarin patents. The Indian company late last year asked the Food and Drug Administration to approve its powder version of Kuvan, saying that BioMarin's patents are invalid, unenforceable or will not be infringed by manufacturing, use or sale.
- Capital Cube•13 days agoDr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 7, 2017
Categories: Yahoo Finance Get free summary analysis Dr. Reddy’s Laboratories Ltd. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Dr. Reddy’s Laboratories Ltd. – Pfizer Inc., Novartis AG Sponsored ADR and Wockhardt Limited Sponsored GDR (PFE-US, NVS-US and WKHZF-US) that have also reported for this period. ... Read more (Read more...)
RDY : Summary for Dr. Reddy's Laboratories Ltd Co - Yahoo Finance
Dr. Reddy's Laboratories Limited (RDY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||43.16 - 43.55|
|52 Week Range||41.60 - 54.73|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||51.87|
|Dividend & Yield||0.30 (0.69%)|
|1y Target Est||N/A|